论文部分内容阅读
[目的]观察二甲双胍联合吡格列酮对2型糖尿病患者免疫状态的影响。[方法]选取2010年6月～2011年4月入住某院治疗的30例2型糖尿病患者作为观察组,同时选取30例健康体检者作为对照组。对照组的健康体检者未给予任何治疗,观察组患者给予口服二甲双胍及盐酸吡格列酮治疗,疗程3个月。观察两组研究对象的外周血T淋巴细胞亚群及免疫球蛋白水平的变化。[结果]与对照组患者治疗前比较,观察组患者治疗前的CD3+、CD4+、CD4+/CD8+、IgM明显降低(P﹤0.01),CD8+、IgA、IgG、C3明显升高(P﹤0.01);而与观察组患者治疗前比较,观察组患者治疗后的CD3+、CD4+/CD8+、IgM明显升高(P﹤0.05),CD8+、IgA、IgG、C3明显降低(P﹤0.05或P﹤0.01)。[结论]二甲双胍联合吡格列酮联合治疗,可以明显改善2型糖尿病患者的免疫状态。
[Objective] To observe the effect of metformin combined with pioglitazone on the immune status of type 2 diabetic patients. [Methods] Thirty patients with type 2 diabetes mellitus admitted to a hospital from June 2010 to April 2011 were selected as the observation group and 30 healthy subjects were selected as the control group. The control group of healthy physical examination did not give any treatment, the observation group was given oral metformin hydrochloride and pioglitazone treatment, the course of 3 months. The changes of peripheral blood T lymphocyte subsets and immunoglobulin levels in two groups were observed. [Results] The levels of CD3 +, CD4 +, CD4 + / CD8 + and IgM in the observation group were significantly lower than those in the control group before treatment (P <0.01), while the levels of CD8 +, IgA, IgG and C3 in the observation group were significantly increased Compared with the observation group, CD3 +, CD4 + / CD8 + and IgM in the observation group were significantly increased (P <0.05) and CD8 +, IgA, IgG and C3 were significantly decreased (P <0.05 or P <0.01). [Conclusion] The combination of metformin and pioglitazone can significantly improve the immune status of type 2 diabetic patients.